Mednet Logo

What is your escalation strategy for chronic GvHD?

How does belumosudil now fit in your approach to steroid refractory chronic graft-versus-host disease?
1 Answer
Mednet Member
Mednet MemberInvited Expert
Hematology · Dana-Farber Cancer Institute
Answered on

There are now several available options for steroid resistant cGVHD. The old standbys - ECP and rituxan are useful in about 30% of patients. Ibrutinib was the first new drug to get FDA approval. Unfortunately, I don't think the real-world experience is anywhere near as good as the trial (Chin et al....

Join for free or sign in to see the full answer